Cancer Research and Treatment

Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population

Chen Wang, Shengyan Liu, Xin Li, Kang Cui, Weijie Zhang, Yabing Du

Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis

Bao-Wen Tian, Cheng-Long Han, Han-Chao Wang, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Xin-Cheng Mao, Jin-Cheng Tian, Jun-Shuai Xue, Long-Shan Yang, Si-Yu Tan, Zhao-Ru Dong, Yu-Chuan Yan, Dong-Xu Wang, Tao Li

Clinical & Experimental Metastasis.2023; 40(4): 255. CrossRef

MelRisk: Using neutrophil-to-lymphocyte ratio to improve risk prediction models for metastatic cutaneous melanoma in the sentinel lymph node

Ryckie G. Wade, Samuel Bailey, Alyss V. Robinson, Michelle C.I. Lo, Howard Peach, Marc D.S. Moncrieff, James Martin

Journal of Plastic, Reconstructive & Aesthetic Surgery.2022; 75(5): 1653. CrossRef

The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy

Yayun Li, Yu Meng, Huiyan Sun, Lin Ye, Furong Zeng, Xiang Chen, Guangtong Deng

Journal of Immunotherapy.2022; 45(1): 43. CrossRef

The pharmacotherapeutic management of nail unit and acral melanomas

Expert Opinion on Pharmacotherapy.2022; 23(11): 1273. CrossRef

Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada

Wei Fang Dai, Jaclyn Beca, Ruth Croxford, Wanrudee Isaranuwatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan

International Journal of Cancer.2021; 148(8): 1910. CrossRef

Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis

Náthali Felícia Mineiro dos Santos Garrett, Ana Cristina Carvalho da Costa, Elaine Barros Ferreira, Giovanni Damiani, Paula Elaine Diniz dos Reis, Christiane Inocêncio Vasques, Gayle E. Woloschak

Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review

Malgorzata Gajdzis, Radoslaw Kaczmarek, Pawel Gajdzis

The Role of Immune Checkpoint Blockade in Uveal Melanoma

Anja Wessely, Theresa Steeb, Michael Erdmann, Lucie Heinzerling, Julio Vera, Max Schlaak, Carola Berking, Markus Vincent Heppt

International Journal of Molecular Sciences.2020; 21(3): 879. CrossRef

Neutrophil diversity and plasticity in tumour progression and therapy

Sebastien Jaillon, Andrea Ponzetta, Diletta Di Mitri, Angela Santoni, Raffaella Bonecchi, Alberto Mantovani

Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis

Kelcie Witges, Leigh Anne Shafer, Ryan Zarychanski, Ahmed M. Abou-Setta, Rasheda Rabbani, Orvie Dingwall, Charles N. Bernstein

Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis

Fausto Petrelli, Raffaele Ardito, Barbara Merelli, Veronica Lonati, Mary Cabiddu, Silvia Seghezzi, Sandro Barni, Antonio Ghidini

Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non–Small-Cell Lung Cancer

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors

Xianhe Xie, Junjin Liu, Haitao Yang, Huijuan Chen, Sijing Zhou, Heng Lin, Ziyuan Liao, Yin Ding, Liting Ling, Xuewen Wang

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Vincenzo Fiorentino, Gianluigi Petrone, Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Marianna Nuti, Gia

Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes

Lucy T. Xu, Pauline F. Funchain, James F. Bena, Manshi Li, Ahmad Tarhini, Eren Berber, Arun D. Singh

Ocular Oncology and Pathology.2019; 5(5): 323. CrossRef

Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis

Tao Jiang, Meng Qiao, Chao Zhao, Xuefei Li, Guanghui Gao, Chunxia Su, Shengxiang Ren, Caicun Zhou

Cancer Immunology, Immunotherapy.2018; 67(5): 713. CrossRef

Prognostic value of neutrophil-to-lymphocyte ratio in melanoma

Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study

Tony Ibrahim, Christine Mateus, Maria Baz, Caroline Robert

Cancer Immunology, Immunotherapy.2018; 67(10): 1571. CrossRef

Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis

Qiaoyun Tan, Shuxia Liu, Caixia Liang, Xiaohong Han, Yuankai Shi

Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma

Francesco S. Mennini, Chiara Bini, Andrea Marcellusi, Michele Del Vecchio

Clinical Drug Investigation.2018; 38(10): 967. CrossRef

A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma

Antoine Finon, Julia Zaragoza, Hervé Maillard, Nathalie Beneton, Guido Bens, Mahtab Samimi, Agnès Caille, Laurent Machet

European Journal of Dermatology.2018; 28(1): 38. CrossRef

Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review

Markus V. Heppt, Theresa Steeb, Justin Gabriel Schlager, Stefanie Rosumeck, Corinna Dressler, Thomas Ruzicka, Alexander Nast, Carola Berking

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

Charissa A. C. Jessurun, Julien A. M. Vos, Jacqueline Limpens, Rosalie M. Luiten